Citations

Mayo Clinic

Showing 10 of 108551 citations.

Reply
Singh, Siddharth , Khera, Rohan , Murad, M. Hassan , Loomba, Rohit , Murad, M Hassan , Loomba, Rohit , Khera, Rohan

Hepatology | December 21, 2015 | Volume: 64 | Issue: 2 | Pages: 694-694

10.1002/hep.28412 | PMID 26690078 Get It

Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database
Hepp, Zsolt, Rosen, Noah , Gillard, Patrick G, Varon, Sepideh F., Mathew, Nitya, Dodick, David W.

Cephalalgia | December 21, 2015 | Volume: 36 | Issue: 9 | Pages: 862-874

10.1177/0333102415621294 | PMID 26692400 Get It

Background Migraine, especially chronic migraine (CM), causes substantial disability; however, health care utilization has not been well characterized among patients receiving different migraine prophylactic treatments. Methods Using a large, US-based, health care claims database, headache-related health care utilization was evaluated among adults with CM treated with onabotulinumtoxinA or oral migraine prophylactic medications (OMPMs). Headache-related health care utilization was assessed at six, nine, and 12 months pre- and post-treatment. The primary endpoint was the difference between pre- and post-index headache-related health care utilization. A logistic regression model was created to test the difference between onabotulinumtoxinA and OMPM-treated groups for headache-related emergency department (ED) visits and hospitalizations. Results Baseline characteristics were comparable between groups. The proportion of patients with ED visits or hospitalizations for a headache-related event decreased after starting onabotulinumtoxinA, but increased after starting an OMPM, for all three cohorts. Regression analyses showed that the odds of having a headache-related ED visit were 21%, 20%, and 19% lower and hospitalization were 47%, 48%, and 56% lower for the onabotulinumtoxinA group compared to the OMPM group for the six-month, nine-month, and 12-month post-index periods, respectively. Conclusions When compared with similar patients who initiated treatment with OMPM, onabotulinumtoxinA was associated with a significantly lower likelihood of headache-related ED visits and hospitalizations.
Use of Personalized Printed 3-Dimensional Kidney Models for Simulation before Nephron Sparing Surgery: Methodology and Examples from a Case Series
Gershman, Boris , Matsumoto, Jane M., King, Bernard F., Leibovich, Bradley C. , Psutka, Sarah P. , Kawashima, Akira , Morris, Jonathan M.

Urology Practice | December 21, 2015 | Volume: 3 | Issue: 2 | Pages: 124-133

10.1016/j.urpr.2015.05.008 | PMID 37592473 Get It

A Critical Review of Repurposing Apomorphine for Smoking Cessation
Morales‐Rosado, Joel A. , Cousin, Margot A. , Ebbert, Jon O. , Klee, Eric W. , Morales-Rosado, Joel A

ASSAY and Drug Development Technologies | December 21, 2015 | Volume: 13 | Issue: 10 | Pages: 612-622

10.1089/adt.2015.680 | PMID 26690764 Get It

The 3‐month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis
Bajaj, Jasmohan S. , Reddy, K. Rajender , Kamath, Patrick S. , García‐Tsao, Guadalupe , Maliakkal, Benedict, Biggins, Scott W. , Thuluvath, Paul J. , Fallon, Michael B. , Subramanian, Ram, Vargas, Hugo E. , O’Leary, Jacqueline G. , Vargas, Hugo, Tandon, Puneeta , Wong, Florence , García–Tsao, Guadalupe , Thacker, Leroy R. , Vargas, Hugo E

Hepatology | December 21, 2015 | Volume: 64 | Issue: 1 | Pages: 200-208

10.1002/hep.28414 | PMID 26690389 Get It

In smaller single‐center studies, patients with cirrhosis are at a high readmission risk, but a multicenter perspective study is lacking. We evaluated the determinants of 3‐month readmissions among inpatients with cirrhosis using the prospective 14‐center North American Consortium for the Study of End‐Stage Liver Disease cohort. Patients with cirrhosis hospitalized for nonelective indications provided consent and were followed for 3 months postdischarge. The number of 3‐month readmissions and their determinants on index admission and discharge were calculated. We used multivariable logistic regression for all readmissions and for hepatic encephalopathy (HE), renal/metabolic, and infection‐related readmissions. A score was developed using admission/discharge variables for the total sample, which was validated on a random half of the total population. Of the 1353 patients enrolled, 1177 were eligible on discharge and 1013 had 3‐month outcomes. Readmissions occurred in 53% (n = 535; 316 with one, 219 with two or more), with consistent rates across sites. The leading causes were liver‐related (n = 333; HE, renal/metabolic, and infections). Patients with cirrhosis and with worse Model for End‐Stage Liver Disease score or diabetes, those taking prophylactic antibiotics, and those with prior HE were more likely to be readmitted. The admission model included Model for End‐Stage Liver Disease and diabetes (c‐statistic = 0.64, after split‐validation 0.65). The discharge model included Model for End‐Stage Liver Disease, proton pump inhibitor use, and lower length of stay (c‐statistic = 0.65, after split‐validation 0.70). Thirty percent of readmissions could not be predicted. Patients with liver‐related readmissions consistently had index‐stay nosocomial infections as a predictor for HE, renal/metabolic, and infection‐associated readmissions (odds ratio = 1.9‐3.0). Conclusions: Three‐month readmissions occurred in about half of discharged patients with cirrhosis, which were associated with cirrhosis severity, diabetes, and nosocomial infections; close monitoring of patients with advanced cirrhosis and prevention of nosocomial infections could reduce this burden. (Hepatology 2016;64:200–208)
Decreased normal NK-cells is a characteristic of T-cell large granular lymphocytic leukemia and is strongly associated with cytopenia
Neff, Jadee , Jevremović, Dragan , Morice, William G. , Neff, Jadee L, Shi, Min , Morice, William George , Jevremovic, Dragan

Leukemia & Lymphoma | December 21, 2015 | Volume: 57 | Issue: 5 | Pages: 1230-1233

10.3109/10428194.2015.1081191 | PMID 26689813 Get It

Evaluation of liver stiffness with magnetic resonance elastography in patients with constrictive pericarditis: Preliminary findings
Fenstad, Eric R. , Dzyubak, Bogdan , Oh, Jae K. , Williamson, Eric E. , Glockner, James F., Young, Phillip M. , Anavekar, Nandan S., Leise, Michael D. , Araoz, Philip A. , Venkatesh, Sudhakar K. , F Glockner, James, Ehman, Richard L. , Dzyubak, Bogdan , Venkatesh, Sudhakar K

Journal of Magnetic Resonance Imaging | December 21, 2015 | Volume: 44 | Issue: 1 | Pages: 81-88

10.1002/jmri.25126 | PMID 26691749 Get It

PurposeTo evaluate with magnetic resonance elastography (MRE) whether patients with constrictive pericarditis (CP) have increased hepatic stiffness. CP results in reduced pericardial compliance, ventricular interdependence, and right heart failure. Patients with untreated CP may develop liver fibrosis and ultimately cirrhosis due to chronic venous congestion. Chronic venous congestion ± fibrosis may lead to increased liver stiffness.Materials and MethodsProspectively, patients with suspected CP underwent 2D transthoracic echocardiography, cardiac MRI, and liver MRE. An automated method was used to draw regions of interest (ROIs) on the stiffness maps to calculate the mean liver stiffness in kilopascals (kPa). A t‐test with α = 0.05 was performed between stiffness values of patients with positive and negative CP findings based on previously published echocardiography criteria.ResultsNineteen patients met inclusion criteria with a mean ± standard deviation (SD) age of 51 ± 16 years. Nine patients (47%) had CP. Mean liver stiffness trended higher in patients with CP compared to those without CP (4.04 kPa vs. 2.46; P = 0.045). Liver stiffness correlated with MRI septal bounce (P = 0.04), inferior vena cava size (P = 0.003), echo abnormal septal motion (P = 0.04), and echo mitral inflow variation >25% (P = 0.02). Only MRI septal bounce predicted CP by echocardiography (P < 0.001).ConclusionCP was associated with increased liver stiffness. The increased stiffness is most likely secondary to chronic hepatic venous congestion and/or fibrosis. MRE may be useful for noninvasive liver stiffness assessment in CP. J. Magn. Reson. Imaging 2016;44:81–88.
Novel X‐linked syndrome of cardiac valvulopathy, keloid scarring, and reduced joint mobility due to filamin A substitution G1576R
Blease, Sophie, Braxton, Alicia, Graves, Julia, He, Weimin , Person, Richard, Slattery, Leah, Bernstein, Jonathan A. , Hudgins, Louanne , Atwal, Paldeep Singh, Atwal, Paldeep S , He, Weimin

American Journal of Medical Genetics Part A | December 21, 2015 | Volume: 170 | Issue: 4 | Pages: 891-895

10.1002/ajmg.a.37491 | PMID 26686323 Get It

Filamin A (FLNA) is known to be involved in intracellular actin binding, cell migration, scaffolding, and signaling. We report a novel X‐linked syndrome characterized by cardiac valvular disease, keloid scarring and reduced joint mobility in male second cousins due to a previously unreported mutation in FLNA. Whole exome sequencing was performed using standard methods and segregation analysis was performed in affected and non‐affected family members. A novel hemizygous c.4726G>A (p.G1576R) mutation in FLNA was detected. Segregation analysis performed on multiple maternal family members showed c.4726G>A (p.G1576R) segregated with disease in an X‐linked inheritance pattern. The findings in these cases are distinct from previously described FLNA related disorders by virtue of decreased joint mobility and spontaneous keloid scarring. They occur in association with a novel mutation and represent a novel genetic syndrome. © 2015 Wiley Periodicals, Inc.
Targeting senescent cells enhances adipogenesis and metabolic function in old age
Xu, Ming , Palmer, Allyson K. , Ding, Husheng, Weivoda, Megan , Pirtskhalava, Tamar , White, Thomas A. , Sepe, Anna, Johnson, Kurt O. , Giorgadze, Nino, Jensen, Michael D. , LeBrasseur, Nathan K. , Tchkonia, Tamar , Kirkland, James L. , Weivoda, Megan M, Stout, Michael B, Stout, Michael B , Xu, Ming , Tchkonia, T , LeBrasseur, Nathan K , Palmer, Allyson K

eLife | December 19, 2015 | Volume: 4 | Issue: No issue available | Pages: No page available

10.7554/elife.12997 | PMID 26687007 Get It

Senescent cells accumulate in fat with aging. We previously found genetic clearance of senescent cells from progeroid INK-ATTAC mice prevents lipodystrophy. Here we show that primary human senescent fat progenitors secrete activin A and directly inhibit adipogenesis in non-senescent progenitors. Blocking activin A partially restored lipid accumulation and expression of key adipogenic markers in differentiating progenitors exposed to senescent cells. Mouse fat tissue activin A increased with aging. Clearing senescent cells from 18-month-old naturally-aged INK-ATTAC mice reduced circulating activin A, blunted fat loss, and enhanced adipogenic transcription factor expression within 3 weeks. JAK inhibitor suppressed senescent cell activin A production and blunted senescent cell-mediated inhibition of adipogenesis. Eight weeks-treatment with ruxolitinib, an FDA-approved JAK1/2 inhibitor, reduced circulating activin A, preserved fat mass, reduced lipotoxicity, and increased insulin sensitivity in 22-month-old mice. Our study indicates targeting senescent cells or their products may alleviate age-related dysfunction of progenitors, adipose tissue, and metabolism.
Choroid plexus–CSF system
Benarroch, Eduardo E.

Neurology | December 19, 2015 | Volume: 86 | Issue: 3 | Pages: 286-296

10.1212/wnl.0000000000002298 | PMID 26683646 Get It